Status:
COMPLETED
Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients
Lead Sponsor:
Taejoon Pharmaceutical Co., Ltd.
Conditions:
Dry Eye
Dry Eye Syndromes
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
In patients with moderate to severe dry eye syndrome, the test drug (HA 0.15% eye drop) or the control drug (cyclosporin 0.05% eye drop) is administered for 12 weeks, and the corneal staining of each ...
Eligibility Criteria
Inclusion
- Male or female, age 20 or over
- Moderate to Severe Dry Eye Disease Patients
- Written informed consent to participate in the trial
Exclusion
- Any laser or ocular surgery within 2 months prior screening
- Use of contact lenses
- Any condition limiting patient's ability to participate in the trial
Key Trial Info
Start Date :
November 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 14 2021
Estimated Enrollment :
438 Patients enrolled
Trial Details
Trial ID
NCT04127851
Start Date
November 12 2019
End Date
October 14 2021
Last Update
June 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taejoon Pharmaceutical Co., Ltd.
Seoul, South Korea